Literature DB >> 18162947

Liposomal amphotericin B associated with severe hyperphosphatemia.

Scott M Sutherland1, David K Hong, Jay Balagtas, Kathleen Gutierrez, Christopher C Dvorak, Minnie Sarwal.   

Abstract

We report 4 patients who developed hyperphosphatemia while receiving liposomal amphotericin B to treat an invasive fungal infection. Resolution of the hyperphosphatemia occurred after transition to amphotericin B lipid complex. This phenomenon may occur more commonly in patients with mild to moderate renal insufficiency.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18162947     DOI： 10.1097/INF.0b013e31815922a3

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  3 in total

1.  Hyperphosphatemia in pediatric oncology patients receiving liposomal amphotericin B.

Authors:  Chad A Knoderer; Holly M Knoderer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

2.  Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.

Authors:  Nicole M Bohm; Katherine C Hoover; Amy E Wahlquist; Yusheng Zhu; Juan Carlos Q Velez
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

3.  Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Authors:  Michaela Döring; Ulrike Hartmann; Annika Erbacher; Peter Lang; Rupert Handgretinger; Ingo Müller
Journal:  BMC Infect Dis       Date:  2012-07-02       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.